Phillippa Dudley

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 461 citations · Full text

Medicine, Oncology, Pharmacology +16

Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT

Jason G. Kettle, S Brown, Claire Crafter et al. · Journal of Medicinal Chemistry · 2012 · 51 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell et al. · Molecular Cancer Therapeutics · 2016 · 42 citations · Full text

Medicine, Oncology, Pharmacology +13

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

Claire Crafter, John P. Vincent, Eric Tang et al. · International Journal of Oncology · 2015 · 37 citations · Full text

Medicine, Oncology, Pharmacology +17